Can pharma tariffs “Make America Manufacture Again”?
As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs…
Trump Tariffs
-
-
China’s mAb and ADC licensing was 3xUS’s in 2024 — will trade tensions slow it?
China’s biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug…
-
Revamping US pharma manufacturing: Trump’s executive order faces industry doubts
US President Donald Trump has issued an executive order aimed at easing regulatory challenges for domestic pharmaceutical producers while imposing…
-
Sanofi commits ‘at least $20bn’ to US manufacturing through 2030
Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the…
-
Bristol Myers Squibb announces $40bn US investment plan over five years
Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research…
-
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
While many pharmaceutical companies have calculated cost hits associated with US tariffs, they are reiterating that looming pharma-specific tariffs create…
-
GSK remains resilient on tariffs as Q1 sales rise 4%
GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it…
-
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US…
-
Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Pharma companies are looking to shore up manufacturing operations in the US to counter international tariffs, but are also bracing…
-
Donald Trump’s first 100 days: Impact on the healthcare industry
When Donald Trump descended a golden escalator at Trump Tower in New York City in 2015 to announce the launch…
